Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive loss of upper and lower motor neurons. Lower motor neurons residing in the spinal cord are particularly vulnerable, and their degeneration leads to the muscle weakness, atrophy, and eventual paralysis that define the clinical presentation of ALS[1]. This page provides a comprehensive analysis of spinal cord motor neuron biology, the molecular mechanisms underlying their degeneration in ALS, and emerging therapeutic strategies targeting these pathways.
Spinal cord motor neurons reside in the anterior (ventral) horn of the spinal cord and are organized somatotopically, with neurons controlling distal muscles located more laterally and those controlling proximal muscles positioned more medially[2]. The largest motor neurons, known as alpha motor neurons, innervate extrafusal muscle fibers and are responsible for voluntary movement. These neurons have cell bodies ranging from 30-70 μm in diameter and possess extensive dendritic trees that can extend over 1 mm from the soma, receiving thousands of synaptic inputs from both upper motor neurons and interneurons.
Motor neurons are classified into two major subtypes based on their physiological properties:
The axons of spinal motor neurons are among the longest in the human body, extending from the spinal cord to peripheral muscles—a distance that can exceed one meter. These axons are myelinated by Schwann cells and possess specialized structural features:
This extensive axonal architecture makes motor neurons uniquely dependent on efficient axonal transport systems and particularly susceptible to disruptions in cellular homeostasis[3].
The hallmark pathological feature of ALS is the accumulation of transactive response DNA-binding protein 43 (TDP-43) in cytoplasmic inclusions within motor neurons[4]. TDP-43 is a nuclear RNA-binding protein that regulates RNA splicing, transport, and translation. In ALS, TDP-43 mislocalizes from the nucleus to the cytoplasm, forming insoluble aggregates that disrupt multiple cellular processes:
RNA Metabolism Dysregulation:
Nuclear Loss of Function:
The identification of TDP-43 aggregates in approximately 95% of ALS cases (excluding those with SOD1 or FUS mutations) has transformed our understanding of disease pathogenesis and provided multiple therapeutic targets[5].
The most common genetic cause of ALS is an expanded GGGGCC hexanucleotide repeat in the first intron of the C9orf72 gene[6]. This mutation accounts for approximately 40% of familial ALS cases and a significant proportion of sporadic cases. The pathogenic mechanisms include:
Toxic Gain-of-Function from Repeat RNAs:
Dipeptide Repeat Protein (DPR) Toxicity:
Loss of C9orf72 Function:
Approximately 20% of familial ALS cases are caused by mutations in the superoxide dismutase 1 (SOD1) gene. While initially thought to cause disease through loss of enzymatic activity, research has established that toxic gain-of-function mechanisms are predominant:
The development of tofersen, an antisense oligonucleotide targeting SOD1, represents a landmark in genotype-specific ALS therapy development[7].
Mutations in the FUS (Fused in Sarcoma) gene cause approximately 5% of familial ALS. FUS is another RNA-binding protein that participates in RNA splicing, transport, and translation. Pathogenic mutations lead to:
Similarly, mutations in TIA1, a stress granule component, cause ALS through dysregulated stress granule dynamics.
The unique architecture of motor neurons, with their exceptionally long axons, makes them critically dependent on axonal transport systems[3:1]. This bidirectional transport system moves cargoes between the cell body and distal terminals:
Kinesin motor proteins transport:
Dynein motor proteins transport:
Multiple studies have documented axonal transport deficits in ALS:
Kinesin and Dynein Dysfunction:
Microtubule Disruption:
Impact on Motor Neuron Viability:
These transport deficits appear early in disease pathogenesis and may represent an upstream event that triggers downstream degeneration[3:2].
Astrocytes in ALS adopt a reactive phenotype and contribute to motor neuron death through multiple mechanisms[8]:
Excitotoxicity:
Secreted Factors:
Metabolic Support Failure:
Resident microglia in the spinal cord become chronically activated in ALS, with both protective and detrimental effects:
Pro-inflammatory Activation:
Beneficial Functions:
The timing and context of microglial activation appear to determine whether the net effect is protective or destructive.
Recent research has highlighted oligodendrocyte involvement in ALS:
Clinical observations and neuropathological studies have revealed that ALS spreads in a predictable pattern[9]:
This propagation pattern has led to hypotheses that disease spreads through:
Emerging evidence supports the concept of templated propagation in ALS:
Neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) in cerebrospinal fluid and blood serve as:
The FDA approval of the NfL assay for ALS diagnosis represents a major advance in biomarker-driven care[10].
Nerve conduction studies and electromyography (EMG) help:
Riluzole: The first FDA-approved ALS drug, believed to work through:
Edaravone: Free radical scavenger approved in 2016:
Tofersen (Qalsody): Antisense oligonucleotide targeting SOD1:
Gene Therapy Approaches:
Cell-Based Therapies:
Small Molecule Approaches:
Repurposed Drugs:
While disease-modifying treatments remain limited, comprehensive symptomatic care improves quality of life:
FF motor neurons are preferentially affected in ALS due to several factors[11]:
The neuromuscular junction (NMJ) is an early site of pathology in ALS:
Understanding these early events has led to the hypothesis that ALS is a distal axonopathy that spreads retrogradely to the cell body[12].
iPSC-Derived Motor Neurons:
Patient-derived induced pluripotent stem cells (iPSCs) offer unprecedented opportunities to model ALS in a human context[13]:
Animal Models:
Recent advances in clinical trial design include:
Spinal cord motor neurons represent a uniquely vulnerable cell population in ALS, with their exceptional size, extensive axonal projections, and high metabolic demands creating multiple susceptibility factors. The convergence of multiple pathological mechanisms—TDP-43 proteinopathy, RNA metabolism defects, axonal transport failure, and glial dysfunction—creates a complex disease process that has proven challenging to address with single-target interventions. However, the development of gene-specific therapies like tofersen provides proof-of-concept that precision medicine approaches can yield meaningful clinical benefits. Future directions include expanding genetic testing, developing combination therapies targeting multiple disease pathways, and implementing biomarker-driven trial designs that accelerate therapeutic development.
Ferraiuolo L, et al. The molecular pathways of motor neuron degeneration in ALS. Neurobiology of Aging. 2011. ↩︎
Nijssen J, et al. Cell type-specific vulnerability in motor neuron diseases. Nature Reviews Neurology. 2017. ↩︎
Kaur SJ, et al. Axonal transport defects and therapeutic strategies in ALS. Brain. 2022. ↩︎ ↩︎ ↩︎
Gao Q, et al. TDP-43 pathology in ALS: from mechanisms to therapeutic targets. Acta Neuropathologica. 2024. ↩︎
Lo TW, et al. TDP-43 and beyond: RNA metabolism in neurodegeneration. Nature Reviews Neuroscience. 2020. ↩︎
Chen H, et al. C9orf72 hexanucleotide repeat expansion: molecular mechanisms and therapeutic targets. Neuron. 2023. ↩︎
Hardiman O, et al. Amyotrophic lateral sclerosis. Nature Reviews Disease Primers. 2017. ↩︎
Clerc T, et al. Astrocyte contributions to motor neuron degeneration in ALS. Glia. 2023. ↩︎
Ravits J, et al. Deconstructing disease: patterns of spread and focal onset in ALS. Nature Reviews Neurology. 2016. ↩︎
Pradat PF, et al. Neurofilament markers in ALS: clinical applications and future directions. Lancet Neurology. 2023. ↩︎
Gennaris M, et al. Motor neuron subtypes in ALS: vulnerability and therapeutic targeting. Nature Reviews Neurology. 2023. ↩︎
Rogers ML, et al. Synaptic dysfunction in ALS: from mechanisms to biomarkers. Brain. 2024. ↩︎
Meyer K, et al. Modeling ALS with iPSC-derived motor neurons: progress and challenges. Cell Stem Cell. 2022. ↩︎